, Tracking Stock Market Picks
Enter Symbol:
Angiodynamics, Inc. (ANGO) [hlAlert]

up 40.32 %

Angiodynamics, Inc. (ANGO) rated Buy with price target $14.50 by Canaccord Genuity

Posted on: Friday,  Jan 8, 2016  8:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy Angiodynamics, Inc. (NASDAQ: ANGO) on 01/08/2016, when the stock price was $10.39. Since
then, Angiodynamics, Inc. has gained 40.33% as of 01/08/2016's recent price of $14.58.
If you would have followed this Canaccord Genuity's recommendation on ANGO, you would have gained 40.32% of your investment in 0 days.

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/8/2016 8:25 AM Buy
10.39 14.50
as of 8/27/2015
1 Week down  -5.44 %
1 Month down  -13.16 %
3 Months down  -11.63 %
1 YTD down  -8.87 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/19/2014 12:00 AM Buy
16.00 20.00
10/9/2012 9:25 AM Hold
11.57 13.50
6/25/2012 9:25 AM Hold
11.90 14.50
7/15/2011 9:25 AM Buy
15.23 16.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy